ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Practice & Policy

Practice & Policy

This video examines how a change to weight-based pembrolizumab dosing in first-line PD-L1–positive lung cancer could save nearly $1 billion in US healthcare costs.

The FDA has granted approval to pembrolizumab for pediatric and adult patients with microsatellite instability (MSI)-high or mismatch repair (MMR)-deficient solid tumors.

The implementation of the Affordable Care Act, which increased insurance coverage, was associated with an increase in the diagnosis of several screenable cancers at an earlier stage.

An NCCN survey taken during the period of congressional debate over new federal healthcare legislation, reports how oncology professionals feel about the possible repeal and replacement of the ACA.

The FDA has sent warning letters to 14 companies marketing dozens of unapproved “miracle cure” products online with fraudulent claims that they prevent or cure cancer.

Ultimately, meaningful value assessment is going to require unbiased comparisons between competing strategies. Decision models are extremely useful in this regard and can provide important insight into cost-effectiveness evaluations.

ASCO has released a statement announcing its opposition to President Trump’s budget outline for FY2018, which would cut about $6 billion in funding to the National Institutes of Health.

Pages

Subscribe to Practice & Policy on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.